Hemophilia Treatment Market by Indication (Type A, Type B), Therapy (Replacement (Recombinant, Plasma Derived), Route of Administration, End User - Global Forecast to 2027
The global hemophilia treatment market is projected to reach USD ~15 billion by 2027 from USD 12 Billion in 2022, at a CAGR of 5% during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
The Hemophilia Treatment market has grown significantly over the last decade and is expected to witness continuous growth in the coming years. Increasing number of hemophilic patients worldwide is the major factor driving the market for recombinant and plasma derived factor VIII and factor IX, which are used to treat hemophilia. In addition, increased diagnosis rate and rise in the use of prophylactic treatment for hemophilia are expected to propel the growth of this market. However, the high cost of recombinant products, serious adverse effects associated with plasma derived products and stringent government regulations are hampering the growth of the global hemophilia treatment market to a certain extent.
In this report, the hemophilia treatment market is segmented by disease, product, route of administration, end user and region. Based on disease type, the hemophilia treatment market is mainly segmented into hemophilia A, hemophilia B and others. Hemophilia A and hemophilia B are divided into three segments, mild, moderate and severe depending on the level of infection by the disease. Based on product, the market is segmented into replacement therapy (recombinant and plasma derived), desmopressin, clot preserving medications, fibrin sealants, and others. Based on the route of administration, the market is segmented into injectable, nasal and oral. The end user segment includes hospitals, clinics and others. The global hemophilia treatment market includes North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia Pacific (China, Japan, Rest of Asia Pacific) and Rest of the World regions.
To know about the assumptions considered for the study, download the pdf brochure
North America is the largest regional segment of the global hemophilia treatment market. However, the APAC region is expected to witness significant growth in the near future. This is primarily due to rising number of hemophilic patients and increasing awareness about technologically advanced products in the region. Moreover, owing to better diagnostic techniques, increasing prophylactic treatment and growing medical research in APAC region, the demand for recombinant and plasma derived products is likely to increase further.
The global hemophilia market was a highly consolidated market as of 2013. However, new local players are emerging and taking efforts to intensify competition. In order to maintain their shares, leading players are continuously adopting various strategies. This increased competitiveness is expected to drive innovation in the market and thereby help the industry to solve existing challenges and meet the needs of the market.
The major players in the global hemophilia market are Bayer Healthcare (Germany), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer Inc. (US), Biogen (US) among others.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.4 PRICING ANALYSIS (BEST EFFORT BASIS)
5.5 VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
5.7 PATENT ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
5.11 KEY STAKEHOLDER AND BUYING CRITERIA
6 HEMOPHILIA TREATMENT MARKET, BY DISEASE
6.1 INTRODUCTION
6.2 HEMOPHILIA A
6.2.1 MILD
6.2.2 MODERATE
6.2.3 SEVERE
6.3 HEMOPHILIA B
6.3.1 MILD
6.3.2 MODERATE
6.3.3 SEVERE
6.3 OTHERS
7 HEMOPHILIA TREATMENT MARKET, BY PRODUCT*
7.1 INTRODUCTION
7.2 REPLACEMENT THERAPY
6.3.1 RECOMBINANT
6.3.2 PLASMA DERIVED
7.3 DESMOPRESSIN
7.4 CLOT-PRESERVING MEDICATIONS
7.5 FIBRIN SEALANTS
7.6 OTHERS (GENE THERAPY, MONOCLONAL ANTIBODIES)
*Tentative segmentation, might change during course of the study
8 HEMOPHILIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
8.2 INJECTABLE
8.3 NASAL
8.3 ORAL
9 HEMOPHILIA TREATMENT MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.3 CLINICS
9.3 OTHERS
11 HEMOPHILIA TREATMENT MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 UK
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 REST OF ASIA PACIFIC
11.5 REST OF THE WORLD
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
12.4 MARKET SHARE ANALYSIS, 2021
12.5 COMPANY EVALUATION QUADRANT
12.6 COMPANY EVALUATION QUADRANT – SME/START-UPS
12.7 COMPANY GEOGRAPHIC FOOTPRINT
12.8 COMPETITIVE SCENARIO
13 COMPANY PROFILES
(Business overview, Products offered, Recent developments & MnM View)*
13.1 BAYER HEALTHCARE
13.2 BIOGEN
13.4 BIOTEST AG
13.5 CSL BEHRING
13.6 FERRING B.V
13.7 GENENTECH
13.8 KEDRION
13.9 NOVO NORDISK
13.10 OCTAPHARMA
13.11 PFIZER
13.12 SANOFI SA
13.13 SWEDISH ORPHAN BIOVITRUM AB
*Tenetative list. 20 key players will be profied. Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE0
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 AVAILABLE CUSTOMIZATIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
Growth opportunities and latent adjacency in Hemophilia Treatment Market